JP2014530818A5 - - Google Patents

Download PDF

Info

Publication number
JP2014530818A5
JP2014530818A5 JP2014535757A JP2014535757A JP2014530818A5 JP 2014530818 A5 JP2014530818 A5 JP 2014530818A5 JP 2014535757 A JP2014535757 A JP 2014535757A JP 2014535757 A JP2014535757 A JP 2014535757A JP 2014530818 A5 JP2014530818 A5 JP 2014530818A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
pharmaceutical composition
methyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014535757A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014530818A (ja
JP6002228B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/058824 external-priority patent/WO2013055577A1/en
Publication of JP2014530818A publication Critical patent/JP2014530818A/ja
Publication of JP2014530818A5 publication Critical patent/JP2014530818A5/ja
Application granted granted Critical
Publication of JP6002228B2 publication Critical patent/JP6002228B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014535757A 2011-10-13 2012-10-05 選択的アンドロゲン受容体調節剤 Active JP6002228B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161546711P 2011-10-13 2011-10-13
US61/546,711 2011-10-13
PCT/US2012/058824 WO2013055577A1 (en) 2011-10-13 2012-10-05 Selective androgen receptor modulators

Publications (3)

Publication Number Publication Date
JP2014530818A JP2014530818A (ja) 2014-11-20
JP2014530818A5 true JP2014530818A5 (enExample) 2015-11-12
JP6002228B2 JP6002228B2 (ja) 2016-10-05

Family

ID=47046879

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014535757A Active JP6002228B2 (ja) 2011-10-13 2012-10-05 選択的アンドロゲン受容体調節剤

Country Status (28)

Country Link
US (1) US8658693B2 (enExample)
EP (1) EP2766350B1 (enExample)
JP (1) JP6002228B2 (enExample)
KR (1) KR20140067102A (enExample)
CN (1) CN103842348B (enExample)
AP (1) AP2014007548A0 (enExample)
AR (1) AR088082A1 (enExample)
AU (1) AU2012321113B2 (enExample)
BR (1) BR112014008668A2 (enExample)
CA (1) CA2847889A1 (enExample)
CL (1) CL2014000895A1 (enExample)
CO (1) CO6910195A2 (enExample)
CR (1) CR20140156A (enExample)
DO (1) DOP2014000075A (enExample)
EA (1) EA201490519A1 (enExample)
EC (1) ECSP14013305A (enExample)
ES (1) ES2626820T3 (enExample)
GT (1) GT201400067A (enExample)
IL (1) IL231440A0 (enExample)
MX (1) MX2014004558A (enExample)
PE (1) PE20141669A1 (enExample)
PH (1) PH12014500808A1 (enExample)
PL (1) PL2766350T3 (enExample)
PT (1) PT2766350T (enExample)
SG (1) SG11201401794YA (enExample)
TN (1) TN2014000136A1 (enExample)
TW (1) TWI449686B (enExample)
WO (1) WO2013055577A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140045856A1 (en) 2012-07-31 2014-02-13 Boehringer Ingelheim International Gmbh 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
TW201534586A (zh) * 2013-06-11 2015-09-16 Orion Corp 新穎cyp17抑制劑/抗雄激素劑
JP6457523B2 (ja) 2013-12-04 2019-01-23 エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングEvotec International GmbH 医薬組成物のためのスルホキシイミン置換キナゾリン
US9682960B2 (en) 2013-12-19 2017-06-20 Endorecherche, Inc. Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
CA2944103A1 (en) 2014-05-07 2015-11-12 Evotec International Gmbh Sulfoximine substituted quinazolines for pharmaceutical compositions
CN109803968A (zh) 2016-08-15 2019-05-24 辉瑞公司 吡啶并嘧啶酮cdk2/4/6抑制剂
MX389592B (es) 2016-09-02 2025-03-20 Suven Life Sciences Ltd Moduladores alostericos positivos del receptor m1 muscarinico
EP3684761A1 (en) 2017-09-18 2020-07-29 Basf Se Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi
AR122725A1 (es) * 2020-06-24 2022-09-28 Celgene Corp Compuestos de unión de cereblon, composiciones de los mismos, y métodos de tratamiento con los mismos
WO2025104624A1 (en) * 2023-11-14 2025-05-22 Pfizer Inc. Synthesis of 1,5-anhydro-3-({5-chloro-4-[4-fluoro-2-(2-hydroxypropan-2-yl)-1-(propan-2-yl)-1h-benzimidazol-6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-d-threo-pentitol

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3594405A (en) * 1968-05-17 1971-07-20 Du Pont Substituted pyranyl anilines as plant growth modifiers
ES2254611T3 (es) * 2001-05-11 2006-06-16 Pfizer Products Inc. Derivados de tiazol.
US8519158B2 (en) * 2004-03-12 2013-08-27 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
ATE412647T1 (de) * 2005-05-13 2008-11-15 Lilly Co Eli Substituierte n-arylpyrrolidine als selektive modulatoren des androgenrezeptors
BRPI0619208A2 (pt) * 2005-11-30 2011-09-20 Astellas Pharma Inc derivado de 2-aminobenzamida c07d 307/14 c07d 307/22 c07d 309/14 c07d 319/12 c07d 401/12 c07d 405/12 c07d 413/12 c07d 417/12
CA2684240A1 (en) * 2007-04-16 2008-10-30 Serenex, Inc. Tetrahydroindole and tetrahydroindazole derivatives
US8190467B2 (en) * 2007-10-19 2012-05-29 Michelle Letendre-Hedlund Methods of identifying environmentally friendly businesses or individuals
BRPI0907844B8 (pt) * 2008-02-22 2021-05-25 Radius Health Inc compostos e método para modular um receptor de andrógeno, processos de preparação e composição farmacêutica dos mesmos e seus usos

Similar Documents

Publication Publication Date Title
JP2014530818A5 (enExample)
JP2018035160A5 (enExample)
JP2019524883A5 (enExample)
JP2021530565A5 (enExample)
JP2016501221A5 (enExample)
JP2011529054A5 (enExample)
JP2015537020A5 (enExample)
JP2013509429A5 (enExample)
JP2013522326A5 (enExample)
CN113784970A (zh) Erk抑制剂及其应用
JP2020511467A5 (enExample)
EP4241772A3 (en) Process for the preparation of compounds useful for treating spinal muscular atrophy
JP2013032389A5 (enExample)
JP2014500861A5 (enExample)
JP2020097577A5 (enExample)
JP2016534063A5 (enExample)
CN103717571B8 (zh) 9‑氨基甲基取代的四环素类化合物
JP2016065042A5 (enExample)
JP2014515013A5 (enExample)
JP2013518107A5 (enExample)
JP2013512277A5 (enExample)
JP2012506872A5 (enExample)
JP2017517565A5 (enExample)
JP2013503134A5 (enExample)
RU2015134420A (ru) Кристаллические формы { [1-циано-5-(4-хлорофеноксид)-4-гидроксид-изохинолин-3-карбонил]-амино} -уксусной кислоты